ACHL
NASDAQ
$1.48
Achilles Therapeutics Plc (ACHL)
Achilles Therapeutics Plc, a clinical-stage immuno-oncology biopharmaceutical company, develops precision T-cell therapies to treat various types of solid tumors. The company is headquartered in London, the United Kingdom.
Sector:
Healthcare
Industry:
Biotechnology
Target: $0.50 (-66.22%)
Market Cap
$63M
P/B Ratio
0.61
Beta (5Y)
0.15
Price Chart
Valuation
Market Cap$63M
P/B0.61
Profitability
EBITDA-$67M
EPS-$1.66
Growth & Risk
Beta (5Y)0.15
Sharpe Ratio1.57